Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.

Autor: Liapis K; Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece. kosliapis@hotmail.com., Papadopoulos V; Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece., Vrachiolias G; Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece., Galanopoulos AG; Department of Clinical Hematology, Georgios Gennimatas Hospital, Athens, Greece., Papoutselis M; Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece., Papageorgiou SG; Second Department of Internal Medicine, Attikon University General Hospital, Athens, Greece., Diamantopoulos PT; First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece., Pappa V; Second Department of Internal Medicine, Attikon University General Hospital, Athens, Greece., Viniou NA; First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece., Kourakli A; Greece Department of Internal Medicine, University Hospital of Patras, Rio, Greece., Τsokanas D; Department of Clinical Hematology, Georgios Gennimatas Hospital, Athens, Greece., Vassilakopoulos TP; Department of Hematology, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece., Hatzimichael E; Department of Hematology, University Hospital of Ioannina, Ioannina, Greece., Bouronikou E; Department of Hematology, University Hospital of Larissa, Larissa, Greece., Ximeri M; Department of Hematology, University General Hospital of Heraklion, Voutes, Heraklion, Greece., Pontikoglou C; Department of Hematology, University General Hospital of Heraklion, Voutes, Heraklion, Greece., Megalakaki A; Department of Hematology, Metaxa Oncology Hospital, Piraeus, Greece., Zikos P; Department of Hematology, Aghios Andreas General Hospital, Patras, Greece., Panayiotidis P; First Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece., Dimou M; First Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece., Karakatsanis S; Department of Hematology, Sotiria General Hospital, Athens, Greece., Papaioannou M; Department of Hematology, AHEPA University Hospital, Thessaloniki, Greece., Vardi A; Department of Hematology and Stem cell Transplantation, Georgios Papanicolaou General Hospital, Thessaloniki, Greece., Kontopidou F; Second Department of Internal Medicine, National and Kapodistrian University of Athens, Hippokratio General Hospital, Athens, Greece., Harchalakis N; Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece., Adamopoulos I; Department of Hematology and Thalassemia, Kalamata General Hospital, Kalamata, Greece., Symeonidis A; Greece Department of Internal Medicine, University Hospital of Patras, Rio, Greece., Kotsianidis I; Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2021 Feb 11; Vol. 11 (2), pp. 30. Date of Electronic Publication: 2021 Feb 11.
DOI: 10.1038/s41408-021-00424-4
Databáze: MEDLINE